Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Ondansetron to reduce neonatal opioid withdrawal severity a randomized clinical trial. Journal of perinatology : official journal of the California Perinatal Association Peltz, G., Jansson, L. M., Adeniyi-Jones, S., Cohane, C., Drover, D., Shafer, S., Wang, M., Wu, M., Govindaswami, B., Jegatheesan, P., Argani, C., Khan, S., Kraft, W. K. 2022

Abstract

To determine if treatment with a 5-HT3 antagonist (ondansetron) reduces need for opioid therapy in infants at risk for neonatal opioid withdrawal syndrome (NOWS).A multicenter, randomized, placebo controlled, double blind clinical trial of ninety (90) infants. The intervention arms were intravenous ondansetron or placebo during labor followed by a daily dose of ondansetron or placebo in infants for five days.Twenty-two (49%) ondansetron-treated and 26 (63%) placebo-treated infants required pharmacologic treatment (p?>?0.05). The Finnegan score was lower in the ondansetron-treated group (4.6 vs. 5.6, p?=?0.02). A non-significant trend was noted for the duration of hospitalization. There was no difference in need for phenobarbital or clonidine therapy, or total dose of morphine in the first 15 days of NOWS treatment.Ondansetron treatment reduced the severity of NOWS symptoms; and there was an indication that it could reduce the length of stay.Clinicaltrials.gov NCT01965704.

View details for DOI 10.1038/s41372-022-01487-2

View details for PubMedID 36030327